Age-related macular degeneration is a leading cause of blindness and affects over 196 million people worldwide. Despite its prevalence, very little is known about the causes or mechanisms of this ...

An estimated 80 percent of patients with the wet form of macular degeneration are diagnosed too late for effective treatment. Now, there's a new computerized test that can detect it earlier than ever ...

Age-related macular degeneration (AMD) causes progressive vision loss in a large number of elderly people, and no treatment ...

A new study suggests that measuring specific immune system proteins in the blood could help predict which patients with intermediate age-related macular degeneration (AMD) are most likely to progress ...

The FDA has approved Eylea HD (aflibercept) 8 mg to treat patients with macular edema following retinal vein occlusion (RVO) with dosing of up to every 8 weeks after an initial monthly dosing period.

Age-related Macular Degeneration (AMD) is characterized by pathological protein- and lipid-rich drusen deposits under the retinal pigment epithelium (RPE) and atrophy of the RPE monolayer in advanced ...

Visible Genomics has launched a set of noninvasive genetic tests aimed at assessing the overall risk of developing age-related macular degeneration (AMD) or progressing with the disease. AMD is a ...

NEW YORK, March 1 (UPI) --Age-related macular degeneration remains a leading cause of vision loss in the United States, but new advancements could help manage and, in some cases, prevent its ...

Scientists have developed a revolutionary laser treatment to prevent blindness. This non-invasive therapy uses ultra-short ...